Arcutis Biotherapeutics, Inc. Common Stock

Day range

—

Open

—

Prev close

$34.05

Volume

46.23K

Market cap

$4.28B

Shares out

125.69M

P/E

150.07

P/S

9.22

P/B

19.40

P/FCF

109.32

ROE

12.9%

ROA

5.8%

Debt/Equity

0.49

Div yield

0.00%

As of Nov 4, 2026

• Quarterly earningsNov 4, 2026

  On November 4, 2026, Arcutis Biotherapeutics, Inc. issued a press release relating to its financial results for the quarter ended September 30, 2026.

• Director appointmentOct 28, 2026

  On October 23, 2026, the Board of Directors (the "Board") of Arcutis Biotherapeutics, Inc. (the "Company") increased the authorized number of directors on the Board from ten to eleven directors and appointed Dr. Robert Scott as a new member of the Board and the Nominating and Corporate Governance Committee of the Board. Dr. Scott was appointed as a Class II director, with a term expiring at the Company's 2028 annual meeting of stockholders.

• Executive officer appointmentAug 5, 2026

  The Company has appointed Robert Lisicki as interim executive vice president, starting August 17, 2026, and as interim chief commercial officer, effective upon Mr. Edwards' departure from the Company on August 21, 2026.

• Executive compensation changeJul 16, 2026

  As a non-employee director, Mr. Peetz will receive compensation in accordance with the Company's non-employee director compensation program, as amended. Pursuant to this program, upon the effective date of his appointment to the Board, Mr. Peetz received an initial stock option award exercisable for 21,486 shares of the Company's common stock, and is eligible for the prorated annual equity award fair valued at approximately $350,000 (allocated 65% to stock options and 35% to restricted stock units) and for the prorated portion of the annual cash retainer in the amount of $50,000 for service on the Board.

• Annual meeting resultsJun 9, 2026

  On June 5, 2026, Arcutis Biotherapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on three proposals... All matters voted on at the Annual Meeting were approved.

Days to cover

9.8

Short interest

20.49M

Avg volume

2.1M

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
  negativeZacks Investment Research· Oct 29, 2026
• Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth
  positiveZacks Investment Research· Oct 28, 2026
• Arcutis Appoints Rob Scott, MD to Board of Directors
  positiveGlobeNewswire Inc.· Oct 28, 2026
• Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
  positiveGlobeNewswire Inc.· Oct 21, 2026
• Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
  positiveGlobeNewswire Inc.· Oct 9, 2026